Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older.
- People who have a type of melanoma (skin or mucosal) that is at stage III, can be surgically removed, and is measurable using standard imaging guidelines.
- People who previously received a type of immunotherapy called anti-PD-1 treatment, as long as that treatment stopped more than 6 months before joining this trial.
- People who previously received targeted therapy for melanoma, as long as that treatment stopped more than 3 months before joining this trial.
Who may not be able to join:
- People whose melanoma has spread to distant parts of the body, as detected by clinical examination or imaging scans.
- People who have a type of melanoma that started in the eye (uveal melanoma).
- People who have had a serious allergic reaction or sensitivity to nivolumab or ipilimumab, or to any of the ingredients in these medicines.
- People whose disease cannot be properly measured or assessed using standard imaging guidelines (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +33(0)662536043
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary objective is to evaluate the efficacy of the intratumoral combination of ipilimumab and nivolumab in terms of pCR or MPR in patients with resectable stage III cutaneous or mucosal melanoma.; The primary objective is to evaluate the tolerability of the intratumoral combination of ipilimumab and nivolumab in patients with resectable stage III cutaneous or mucosal melanoma.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.